Xiaochun Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaochun Zhang has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Angela C. Hirbe
Washington University School of Medicine
148 shared publications - Christine A. Pratilas
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, USA
140 shared publications - Kai Pollard
Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
140 shared publications - Dana C. Borcherding
Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri
82 shared publications - Kevin He
Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri
82 shared publications - Yang Lyu
Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri
82 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S10 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Supplemental Fig.S10. Treatment with deucravacitinib and/or mirdametinib did not decrease mouse body weight over time.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Supplemental Fig.S10. Treatment with deucravacitinib and/or mirdametinib did not decrease mouse body weight over time.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression
Supplementary Table S5. Abbreviated list of top kinase inhibitory compounds predicted to be effective against MPNSTs from C-Map analyses of the MPNST transcriptome from NF1 patients.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression
Supplementary Table S5. Abbreviated list of top kinase inhibitory compounds predicted to be effective against MPNSTs from C-Map analyses of the MPNST transcriptome from NF1 patients.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Supplemental Fig.S6. TYK2 inhibition decreases expression of STAT3 target genes and increases expression of genes in the MEK/MAPK signaling cascade in MPNST cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Supplemental Fig.S6. TYK2 inhibition decreases expression of STAT3 target genes and increases expression of genes in the MEK/MAPK signaling cascade in MPNST cells.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Supplemental Fig.S5. Validation of select gene expression changes with TYK2 inhibitor treatment that were identified by qPCR array. JH-2-002 cells were incubated with 40 µMWU-12 or control for 48 hours, and gene expression was analyzed by qPCR for select(A)up-regulated or(B)down-regulated genes.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Supplemental Fig.S5. Validation of select gene expression changes with TYK2 inhibitor treatment that were identified by qPCR array. JH-2-002 cells were incubated with 40 µMWU-12 or control for 48 hours, and gene expression was analyzed by qPCR for select(A)up-regulated or(B)down-regulated genes.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression
Supplementary Figure S6. Analysis of helper (CD4) and pan (CD3) T cells in combination therapysensitive versus combination therapy-resistant MPNSTs
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression
Supplementary Figure S6. Analysis of helper (CD4) and pan (CD3) T cells in combination therapysensitive versus combination therapy-resistant MPNSTs
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression
Supplementary Table S4. Primers for qRT-PCR analyses
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression
Supplementary Table S4. Primers for qRT-PCR analyses
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression
Supplementary Figure S5. Evaluation of differentially expressed genes (DEGs) and tumor infiltrating immune cells (plasma cells and B cells) in drug-treated de novo MPNSTs.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression
Supplementary Figure S5. Evaluation of differentially expressed genes (DEGs) and tumor infiltrating immune cells (plasma cells and B cells) in drug-treated de novo MPNSTs.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression
Supplementary Table S3. Cluster of differentiation (CD) markers used to delineate immune cell populations after gating on CD45+ live cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression
Supplementary Table S3. Cluster of differentiation (CD) markers used to delineate immune cell populations after gating on CD45+ live cells.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Supplemental Fig.S4. TYK2 knockout decreases proliferation of MPNST-724 cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Supplemental Fig.S4. TYK2 knockout decreases proliferation of MPNST-724 cells.